GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: humanized OKT3 | MGA031 | PRV-031 | teplizumab-mzwv | Tzield®
teplizumab is an approved drug (FDA (2022))
Compound class:
Antibody
Comment: Teplizumab is a humanized anti-CD3e monoclonal antibody that was originally developed as an immunomodulatory agent. Structurally it is a modified version of the mouse antibody muromonab-CD3 (mOKT3) that has been used to reverse steroid-resistant renal allograft rejection. Alterations in the OKT3 CH2 domain disrupt Fcγ receptor binding, and blocks antibody-mediated effector cells functions and cytokine release [5,7]. It was advanced to extended clinical evaluations for potential to protect pancreatic β-cells in newly diagnosed type 1 diabetes (T1D) patients [4,6], following evidence that it impaired expansion of alloreactive anti-β cell T cells [5], and that a single short course of teplizumab treatment could induce a long-lasting improvement in patients' C-peptide responses and clinical parameters (including preservation of insulin production) in the early stages of T1D [2-3].
|
Classification  |
|
| Compound class | Antibody |
| Approved drug? | Yes. US FDA (2022) |
| International Nonproprietary Names |
|
| INN number | INN |
| 8869 | teplizumab |
| Synonyms |
| humanized OKT3 | MGA031 | PRV-031 | teplizumab-mzwv | Tzield® |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 92 |
| Other databases | |
| GtoPdb PubChem SID | 473153840 |
| Search PubMed clinical trials | teplizumab |
| Search PubMed titles | teplizumab |
| Search PubMed titles/abstracts | teplizumab |
